Cargando…
Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
Immune checkpoint inhibitors (ICIs) are used increasingly to treat more than 17 cancers and have shown promising therapeutic results. However, ICI use can result in a variety of immune-related adverse events (IRAEs) which can occur in any organ, including the kidneys. Acute kidney injury (AKI) is th...
Autores principales: | Miao, Jing, Sise, Meghan E., Herrmann, Sandra M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479679/ https://www.ncbi.nlm.nih.gov/pubmed/37674988 http://dx.doi.org/10.3389/fneph.2022.1017921 |
Ejemplares similares
-
Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond
por: Tinawi, Mohammad, et al.
Publicado: (2020) -
Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study
por: Becerir, Tülay, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021) -
Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab
por: Efe, Orhan, et al.
Publicado: (2021) -
Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)